Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review.

Swart AM, Burdett S, Ledermann J, Mook P, Parmar MK.

Ann Oncol. 2008 Apr;19(4):688-95. Epub 2007 Nov 15. Review.

PMID:
18006894
2.

A systematic overview of chemotherapy effects in ovarian cancer.

Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):340-60. Review.

PMID:
11441940
3.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G.

Health Technol Assess. 2001;5(28):1-110. Review.

4.

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.

Lawrie TA, Rabbie R, Thoma C, Morrison J.

Cochrane Database Syst Rev. 2013 Oct 21;(10):CD010482. doi: 10.1002/14651858.CD010482.pub2. Review.

PMID:
24142521
5.

Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin.

Dittrich Ch, Sevelda P, Salzer H, Obermair A, Speiser P, Breitenecker G, Schemper M, Kaider A; Austrian Ovarian Cancer Study Group.

Eur J Cancer. 2003 May;39(8):1129-40. Erratum in: Eur J Cancer. 2004 Mar;40(4):627.

PMID:
12736113
6.

Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.

Covens A, Carey M, Bryson P, Verma S, Fung Kee Fung M, Johnston M.

Gynecol Oncol. 2002 Apr;85(1):71-80. Review.

PMID:
11925123
7.

Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.

Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, Fruehauf JP.

Gynecol Oncol. 2002 Oct;87(1):8-16.

PMID:
12468336
8.

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.

Jaaback K, Johnson N, Lawrie TA.

Cochrane Database Syst Rev. 2016 Jan 12;(1):CD005340. doi: 10.1002/14651858.CD005340.pub4. Review.

PMID:
26755441
9.

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

Winter-Roach BA, Kitchener HC, Lawrie TA.

Cochrane Database Syst Rev. 2012 Mar 14;(3):CD004706. doi: 10.1002/14651858.CD004706.pub4. Review. Update in: Cochrane Database Syst Rev. 2015;(12):CD004706.

10.

A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer.

Hess LM, Benham-Hutchins M, Herzog TJ, Hsu CH, Malone DC, Skrepnek GH, Slack MK, Alberts DS.

Int J Gynecol Cancer. 2007 May-Jun;17(3):561-70.

PMID:
17504373
11.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

12.

Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.

Ozols RF, Bookman MA, du Bois A, Pfisterer J, Reuss A, Young RC.

Gynecol Oncol. 2006 Oct;103(1):1-6. Epub 2006 Aug 10. No abstract available.

PMID:
16904166
13.

Optimal chemotherapy treatment for women with recurrent ovarian cancer.

Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P.

Curr Oncol. 2007 Oct;14(5):195-208.

14.

Principle and evolving role of intraperitoneal chemotherapy in ovarian cancer.

Fujiwara K, Nagao S, Aotani E, Hasegawa K.

Expert Opin Pharmacother. 2013 Sep;14(13):1797-806. doi: 10.1517/14656566.2013.820705. Epub 2013 Aug 6. Review.

PMID:
23915009
15.

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

Lawrie TA, Winter-Roach BA, Heus P, Kitchener HC.

Cochrane Database Syst Rev. 2015 Dec 17;(12):CD004706. doi: 10.1002/14651858.CD004706.pub5. Review.

PMID:
26676202
16.

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

Winter-Roach BA, Kitchener HC, Dickinson HO.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD004706. doi: 10.1002/14651858.CD004706.pub3. Review. Update in: Cochrane Database Syst Rev. 2012;3:CD004706.

PMID:
19588360
17.

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.

International Collaborative Ovarian Neoplasm Group.

Lancet. 2002 Aug 17;360(9332):505-15. Erratum in: Lancet. 2003 Feb 22;361(9358):706.

PMID:
12241653
18.

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.

Jaaback K, Johnson N.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005340. Review. Update in: Cochrane Database Syst Rev. 2011;(11):CD005340.

PMID:
16437527
19.

Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.

Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S; EORTC-ACTION collaborators. European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm.

J Natl Cancer Inst. 2003 Jan 15;95(2):113-25.

PMID:
12529344
20.

Medical therapy of advanced malignant epithelial tumours of the ovary.

Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.

Forum (Genova). 2000 Oct-Dec;10(4):323-32. Review.

PMID:
11535983

Supplemental Content

Support Center